Research Articles | Page 28 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes Apr 2019 Blood Myelodysplastic Syndromes (MDS)
Rethinking clinical trial endpoints in myelodysplastic syndromes. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. Jan 2019 Crit Rev Oncol Hematol Myelodysplastic Syndromes (MDS)
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 Apr 2020 Leukemia Research Reports Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study Jul 2020 Leukemia Research Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) Jan 2021 Cancer Causes & Control : CCC Myelodysplastic Syndromes (MDS)
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Mar 2021 Cancers Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS)
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review Jul 2023 Experimental Hematology & Oncology Myelodysplastic Syndromes (MDS)
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome May 2024 Journal of Pediatric Hematology/Oncology Aplastic Anemia
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)